Last reviewed · How we verify
Rocuronium bromide (Zemuron)
Rocuronium bromide is a non-depolarizing neuromuscular blocking agent that competitively inhibits the nicotinic acetylcholine receptor at the neuromuscular junction.
Rocuronium bromide is a non-depolarizing neuromuscular blocking agent that competitively inhibits the nicotinic acetylcholine receptor at the neuromuscular junction. Used for Endotracheal intubation, Surgical procedures requiring muscle relaxation.
At a glance
| Generic name | Rocuronium bromide (Zemuron) |
|---|---|
| Also known as | ORG 9426, SCH 900085, Zemuron, ORG 9426, SCH 900085, Zemuron |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Non-depolarizing neuromuscular blocking agent |
| Target | Nicotinic acetylcholine receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | Phase 3 |
Mechanism of action
This inhibition prevents acetylcholine from binding to the receptor, leading to muscle paralysis. The effect is reversible with anticholinesterases such as neostigmine. Rocuronium bromide has a rapid onset of action and a short duration of effect.
Approved indications
- Endotracheal intubation
- Surgical procedures requiring muscle relaxation
Common side effects
- Hypotension
- Bradycardia
- Respiratory depression
- Muscle weakness
- Anaphylaxis
Key clinical trials
- The Relationship Between Opioid-Free Anesthesia and Postoperative Agitation-Delirium and Quality of Recovery in Pediatric Ear, Nose, and Throat Cases Monitored With Perioperative Bispectral Index
- Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NA)
- Association of Sarcopenia With Rocuronium Use in Liver Transplant Recipients (NA)
- Awareness Neuraxial Versus General Anesthesia in Frail Patients Undergoing Laparoscopic or Robotic Abdominopelvic Surgery. (NA)
- Deep Versus Moderate Neuromuscular Blocking (NA)
- Effect of Neuromuscular Block Depth on Driving Pressure and Postoperative Respiratory Events in Abdominal Surgeries (NA)
- Safety and Efficacy of HRS-9190 Compared to Rocuronium for Bolus Maintenance in Adults (PHASE2)
- A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 and 24 Months Old (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rocuronium bromide (Zemuron) CI brief — competitive landscape report
- Rocuronium bromide (Zemuron) updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI